相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dermatology, cosmetic and well-being
C. Battie et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2011)
Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
V. Hirsh
Current Oncology (2011)
Skin care management in cancer patients: an evaluation of quality of life and tolerability
Ann Cameron Haley et al.
SUPPORTIVE CARE IN CANCER (2011)
Subacute Cutaneous Lupus Erythematosus Exacerbated or Induced by Chemotherapy
Alisa A. Funke et al.
ARCHIVES OF DERMATOLOGY (2010)
Effects of Epidermal Growth Factor Receptor Inhibitor-Induced Dermatologic Toxicities on Quality of Life
Smita S. Joshi et al.
CANCER (2010)
Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer
Jan Ouwerkerk et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2010)
Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer
J. Ocvirk et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)
Skin toxicities of targeted therapies
Siegfried Segaert et al.
EUROPEAN JOURNAL OF CANCER (2009)
Look Good Feel Better Workshops: A Big Lift for Women with Cancer
Linda R. Taggart et al.
JOURNAL OF CANCER EDUCATION (2009)
NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer
Barbara Burtness et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147
Aminah Jatoi et al.
ONCOLOGY (2009)
Evaluating beauty care provided by the hospital to women suffering from breast cancer: qualitative aspects
Philippe Amiel et al.
SUPPORTIVE CARE IN CANCER (2009)
Maquillage correcteur médical en post chimiothérapie
C. Merial-Kieny et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2008)
Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity
Tal Grenader et al.
CLINICAL LUNG CANCER (2008)
Do Patients Die from Rashes from Epidermal Growth Factor Receptor Inhibitors? A Systematic Review to Help Counsel Patients About Holding Therapy
Aminah Jatoi et al.
ONCOLOGIST (2008)
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
J. Bernier et al.
ANNALS OF ONCOLOGY (2008)
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
Bret Wacker et al.
CLINICAL CANCER RESEARCH (2007)
Impact of cosmetic care on quality of life in breast cancer patients during chemotherapy and radiotherapy: an initial randomized controlled study
G. Titeca et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
Minnelly Luu et al.
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE (2007)
Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management
Jenny C. Hu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results
Susan L. Boone et al.
ONCOLOGY (2007)
Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
A. F. S. Galimont-Collen et al.
EUROPEAN JOURNAL OF CANCER (2007)
Functional assessment of a skin care system in patients on chemotherapy
J. W. Fluhr et al.
SKIN PHARMACOLOGY AND PHYSIOLOGY (2007)
EGFR activation and ultraviolet light-induced skin carcinogenesis
Taghrid B. El-Abaseri et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2007)
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
Thomas J. Lynch et al.
ONCOLOGIST (2007)
The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome
M. E. Lacouture et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
Anna Liza C. Agero et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Description and management of cutaneous side effects during cetuximab or erlotinib treatments:: A prospective study of 30 patients
Esther Roe et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cutaneous adverse effects with HER1/EGFR-targeted agents:: Is there a silver lining?
R Peréz-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
HER1/EGFR inhibitor-associated rash:: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
R Pérez-Soler et al.
ONCOLOGIST (2005)
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
S Segaert et al.
ANNALS OF ONCOLOGY (2005)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy
M Wolf et al.
CLINICAL CANCER RESEARCH (2004)
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours
W Jacot et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Keratinocyte apoptosis induced by ultraviolet B radiation and CD95 ligation -: Differential protection through epidermal growth factor receptor activation and Bcl-xL expression
M Jost et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
分享论文
